NEW DELHI — In a major regulatory sweep, the Central Government has issued a stern warning to pharmaceutical entities over the unauthorised sale and promotion of GLP-1 receptor agonist-based weight-loss drugs. On April 1, 2026, the Ministry of Health and Family Welfare cautioned that businesses violating drug laws will face licence cancellation, heavy fines, and legal prosecution.
Nationwide Inspections and Audits
The Drugs Controller General of India (DCGI), in coordination with State Regulators, has already launched a massive enforcement drive. As of early April, authorities have audited and inspected 49 entities, including:
- Online pharmacy warehouses and digital platforms.
- Retail pharmacies and wholesalers.
- Wellness clinics and weight-loss centres.
These inspections targeted serious violations such as selling prescription-only drugs over-the-counter (OTC), improper prescription practices, and misleading marketing.
Rising Misuse and Health Risks
The crackdown follows a surge in the availability of multiple generic variants of blockbuster drugs like semaglutide, liraglutide, and tirzepatide. Following the patent expiry of some molecules, prices in India have dropped by 50–70%, leading to increased off-label use without medical oversight.
The government has highlighted that these drugs are not “quick-fix” solutions and carry severe health risks if misused, including:
- Common Side Effects: Nausea, vomiting, and dizziness.
- Severe Complications: Pancreatitis, kidney injury, bowel obstruction, and potential risk of thyroid cancer.
- Cosmetic Impact: Rapid facial fat loss, leading to “sunken eyes” and sagging jowls.
Strict Prescription Norms
The Central Drugs Standard Control Organisation (CDSCO) has reiterated that these medications are approved in India only for use under the guidance of specialists. Currently, they can only be prescribed by endocrinologists, internal medicine specialists, and cardiologists.
Ban on Surrogate Advertising
The Ministry has also prohibited all forms of direct or indirect promotion. This includes surrogate advertisements disguised as “obesity awareness” campaigns and influencer collaborations that create brand recall. Manufacturers have been directed to ensure all promotional activities strictly comply with the Drugs and Cosmetics Act, 1940.
By tightening the regulatory net, the government aims to ensure that these breakthrough medications remain a tool for clinical treatment rather than a hazardous lifestyle shortcut.
